# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K083171   
B. Purpose for Submission: Addition of 679 base pairs of wild type CFTR sequence to previously cleared Introl™ CF Panel I Control (k060070)   
C. Measurand: Controls for assays detecting Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutations and variants   
D. Type of Test: Assayed quality control material   
E. Applicant: Maine Molecular Quality Controls, Inc. (MMQCI)   
F. Proprietary and Established Names: Introl™ CF Panel I Control

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.5910 DNA quality control material for genetic testing   
2. Classification: Class II   
3. Product code: NZB, Quality Control material, genetics, DNA   
4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The intended use is the same as the previous cleared Introl™ CF Panel I Control (k060070) which states:

The Introl™ CF Panel I Control is intended for in vitro diagnostic use as a quality control to monitor analytical performance of the extraction, amplification and detection steps of diagnostic assays used in the detection of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutations and variants. This product is intended to be extracted and analyzed routinely with each CFTR assay run.

The INTROL™ CF Panel I Control is designed to monitor the detection of 38 CFTR mutations associated with cystic fibrosis, including the 23 mutations recommended for testing by American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG). The INTROL™ CF Panel I Control also monitors 3 polymorphisms (I506V, I507V, F508C) and the 5/7/9T variants.

2. Indication(s) for use: Same as the intended use   
3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Not applicable

# I. Device Description:

The formulation of the modified and cleared INTROL™ CF Panel I Control is the same: INTROL™ CF Panel I Control consists of synthetic CFTR DNA suspended in a matrix of synthetic DNA targets, carrier DNA of a non-human species, preservatives, dye, and stabilizers. CFTR DNA is stabilized in the matrix and released when processed through common extraction methods as if it were a whole blood specimen.

INTROL™ CF Panel I Control modifications from the cleared panel:

CFTR DNA has been modified as follows:   
1. Exon 3: additional 106 nucleotides $_ 3 \cdot$   
2. Exon 5: additional 184 nucleotides 3’   
3. Exon 14b: additional 100 nucleotides $5 '$ and additional 289 nucleotides 3’

Table I: Number of Intronic Bases Flanking Each Exon of INTROL™ CF Panel I Control   

<table><tr><td rowspan=1 colspan=3>Cleared INTROLTM CF Panel I Control</td><td rowspan=1 colspan=3>Modified INTROLTM CF Panel I Control</td></tr><tr><td rowspan=1 colspan=1>EXON</td><td rowspan=1 colspan=1>5&#x27;</td><td rowspan=1 colspan=1>3&#x27;</td><td rowspan=1 colspan=1>EXON</td><td rowspan=1 colspan=1>5&#x27;</td><td rowspan=1 colspan=1>3&#x27;</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>273</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>273</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>231*</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>307</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>307</td><td rowspan=1 colspan=1>270*</td></tr><tr><td rowspan=1 colspan=1>6A</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>6A</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>6B</td><td rowspan=1 colspan=1>255</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>6B</td><td rowspan=1 colspan=1>255</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>134</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>402</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>402</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>339</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>339</td><td rowspan=1 colspan=1>246</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>235</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>289</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>128</td></tr><tr><td rowspan=1 colspan=1>14A</td><td rowspan=1 colspan=1>385</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>14A</td><td rowspan=1 colspan=1>385</td><td rowspan=1 colspan=1>250</td></tr><tr><td rowspan=1 colspan=1>14B</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>14B</td><td rowspan=1 colspan=1>365*</td><td rowspan=1 colspan=1>548*</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>133</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>259</td></tr><tr><td rowspan=1 colspan=1>17A</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>315</td><td rowspan=1 colspan=1>17A</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>315</td></tr><tr><td rowspan=1 colspan=1>17B</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>17B</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>154</td></tr><tr><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>244</td><td rowspan=1 colspan=1>211</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>251</td></tr><tr><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>443</td><td rowspan=1 colspan=1>313</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>443</td><td rowspan=1 colspan=1>313</td></tr><tr><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>585</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>585</td><td rowspan=1 colspan=1>235</td></tr><tr><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>181</td></tr><tr><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>222</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>222</td></tr></table>

\*modification

# J. Substantial Equivalence Information:

1. Predicate device name(s): INTROL™ CF Panel I Control

2. Predicate 510(k) number(s): k060070

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>PREDICATE</td><td rowspan=1 colspan=1>MODIFIED</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Monitor analytical performanceof extraction, amplification, anddetection steps of CFTR mutationdetection assays.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Formulation</td><td rowspan=1 colspan=1>Synthetic (recombinant) DNAwith non-human carrier DNA,preservatives, dye and stabilizers</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Physical Format</td><td rowspan=1 colspan=1>Ready-to-use liquid</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Packaging</td><td rowspan=1 colspan=1>Polypropylene bottles</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Steps Monitored</td><td rowspan=1 colspan=1>Extraction, Amplification andDetection</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Recommended Storage</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Directions for Use</td><td rowspan=1 colspan=1>Handle control in the samemanner as the patient sample</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Method to ValidateCFTR Sequence</td><td rowspan=1 colspan=1>Bi-directional sequencing</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Method to Verify eachLot</td><td rowspan=1 colspan=1>FDA-cleared CFTR detectionassay, Bi-directional sequencing</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Modified</td></tr><tr><td rowspan=1 colspan=1>Gene Segment SNPs</td><td rowspan=1 colspan=1>CFTR (38 mutations; 4 variants)</td><td rowspan=1 colspan=1>Additional 679 base pairsof wild type CFTRsequence to the existingSNPs</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Class II Special Controls Guidance Document: Quality Control Material for Cystic Fibrosis Nucleic Acid Assays

L. Test Principle: Not applicable

M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Lot-to-lot reproducibility Three builds of CF Panel I were manufactured using the same SOPs as for FDA-cleared

CF panel I with calculations adjusted for the new size plasmids. The first two builds are comprised of five bottles each. Each bottle contained specific clones, independently manufactured. The third build is comprised of three bottles, each containing different clones independently manufactured. All lots were tested using the xTAG™ Cystic Fibrosis Kit, eSensor and other amplification methods and found to give the correct calls.

Table 3: Modified INTROL™ CF Panel 1, Build 1   

<table><tr><td rowspan=1 colspan=1>Lot Number /bottle</td><td rowspan=1 colspan=1>Method (s)</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=2 colspan=1>K08JUN06/ a</td><td rowspan=1 colspan=1>Other Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>xTAG™ Cystic Fibrosis Kit</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=3 colspan=1>L08JUN06/ b</td><td rowspan=1 colspan=1>Other Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>xTAG™ Cystic Fibrosis Kit</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>eSensor</td><td rowspan=1 colspan=1>All correct except 2 transcription errors</td></tr><tr><td rowspan=3 colspan=1>A09JUN06/c</td><td rowspan=1 colspan=1>Other Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>xTAG™ Cystic Fibrosis Kit</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>eSensor</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=2 colspan=1>B09JUN06/ d</td><td rowspan=1 colspan=1>Other Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>xTAG™ Cystic Fibrosis Kit</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=2 colspan=1>C09JUN06/ e</td><td rowspan=1 colspan=1>Other Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>xTAG™ Cystic Fibrosis Kit</td><td rowspan=1 colspan=1>All calls correct</td></tr></table>

Table 4: Modified INTROL™ CF Panel 1, Build 2 and 3   

<table><tr><td rowspan=1 colspan=1>Lot Number /bottle</td><td rowspan=1 colspan=1>Method (s)</td><td rowspan=1 colspan=1>Results</td></tr><tr><td rowspan=1 colspan=1>B16JAN07/ a</td><td rowspan=1 colspan=1>All Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>C16JAN07/ b</td><td rowspan=1 colspan=1>All Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>D16JAN07/ c*</td><td rowspan=1 colspan=1>All Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>E16JAN07/ d</td><td rowspan=1 colspan=1>All Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>F16JAN07/e</td><td rowspan=1 colspan=1>All Amplification Methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>A05OCT07/ a</td><td rowspan=1 colspan=1>All Amplification methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>B05OCT07/ b</td><td rowspan=1 colspan=1>All Amplification methods</td><td rowspan=1 colspan=1>All calls correct</td></tr><tr><td rowspan=1 colspan=1>C05OCT07/ c*</td><td rowspan=1 colspan=1>All Amplification methods</td><td rowspan=1 colspan=1>All calls correct</td></tr></table>

\*Bottle c contains same set of plasmids as found separately in bottles d and e

b. Linearity/assay reportable range: Reference: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Same as k060070   
d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable   
f. Assay cut-off: Not applicable

2. Comparison studies:

The three batches of modified INTROL CF Panel I Control were tested in the following CFTR detection assays: xTAG $^ \mathrm { \textregistered }$ (Luminex/ TmBioscience), eSensor $^ \mathrm { \textregistered }$ CFCD (Osmetech), and InPlex $^ \mathrm { \textregistered }$ (Third Wave) which require the additional CFTR sequence of the modified INTROL CF Panel I Control in order to detect Control alleles $7 1 1 + 1 \mathrm { G } > \mathrm { T }$ and $2 7 8 9 + 5 \mathrm { G } { \mathrm { > } } \mathrm { A }$ . All genotype calls were the same as for the predicate INTROL CF Panel I Control with the exception that $7 1 1 + 1 \mathrm { G } > \mathrm { T }$ and $2 7 8 9 + 5 \mathrm { G } { \mathrm { > } } \mathrm { A }$ were detected by all assays.

# Risk analysis

A risk analysis using Failure Modes and Effects Analysis (FMEA) was performed to assess the impact of the modifications. Results showed that the design outputs of modified INTROL CF Panel I meet design inputs in conformance with design control requirements as specified in 21 CFR 820.30.

3. Clinical studies: Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.